MCID: NRN004
MIFTS: 50

Neuroendocrine Tumor malady

Neuronal diseases category

Aliases & Classifications for Neuroendocrine Tumor

About this section
Sources:
8Disease Ontology, 10DISEASES, 44Novoseek, 61UMLS, 27ICD9CM, 33MeSH, 39NCIt, 56SNOMED-CT
See all sources

Aliases & Descriptions for Neuroendocrine Tumor:

Name: Neuroendocrine Tumor 8 10
Neuroendocrine Tumors 44 61
 
Carcinoma Neuroendocrine 44
Neuroendocrine Neoplasm 8


Classifications:



External Ids:

Disease Ontology8 DOID:169
ICD9CM27 209-209.99, 209
MeSH33 D018358
NCIt39 C3809

Summaries for Neuroendocrine Tumor

About this section
Wikipedia:64 Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous... more...

MalaCards based summary: Neuroendocrine Tumor, also known as neuroendocrine tumors, is related to multiple endocrine neoplasia and cushing's syndrome. An important gene associated with Neuroendocrine Tumor is CHGA (chromogranin A (parathyroid secretory protein 1)), and among its related pathways are Adenylate cyclase activating neuropeptides and SIDS Susceptibility Pathways. The compounds lithium chloride and ghrp-6 have been mentioned in the context of this disorder. Affiliated tissues include pancreas, lung and liver, and related mouse phenotypes are digestive/alimentary and normal.

Disease Ontology:8 An endocrine gland cancer that has material basis in neuroendocrine cells.

Related Diseases for Neuroendocrine Tumor

About this section

Diseases related to Neuroendocrine Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 192)
idRelated DiseaseScoreTop Affiliating Genes
1multiple endocrine neoplasia31.4CHGA, CALCA
2cushing's syndrome31.3SST
3gastrinoma31.2CHGA, SST
4paraganglioma31.0CHGA, SST, CALCA
5acromegaly30.8SST, GHRL, GGH
6hypoglycemia30.7GHRL, SST, CHGA
7pancreatic cancer30.5CDX2, SST, CHGA
8vipoma30.5SST, CALCA
9pheochromocytoma30.5CHGA, ASCL1, SST, CALCA, CDX2
10phaeochromocytoma30.5CHGA, CALCA
11pituitary adenoma30.5MKI67, CHGA, SST, GHRL
12gastritis30.4GHRL, CDX2
13somatostatinoma30.4CALCA, SST, CHGA
14thyroid cancer30.3CHGA, SST, CALCA, NKX2-1
15insulinoma30.2CPE, CHGA, SST, GHRL, CALCA
16merkel cell carcinoma30.1CHGA, SST, NKX2-1
17diarrhea30.0CPE, CHGA, SST, CALCA
18atrophic gastritis29.9CDX2, GHRL, SST, CHGA
19lung cancer29.7CDX2, NKX2-1, CHGA, MKI67
20adenocarcinoma29.7MKI67, CHGA, ASCL1, SST, GHRL, NKX2-1
21hepatocellular carcinoma29.4CDX2, NKX2-1, GHRL, MKI67
22adenoma29.1MKI67, CHGA, ASCL1, SST, GHRL, CALCA
23carcinoid syndrome28.9MKI67, TPH1, CDX2, GGH, NKX2-1, CALCA
24pancreatitis11.1
25hepatitis10.7
26pulmonary neuroendocrine tumor10.7
27gastrointestinal neuroendocrine tumor10.6
28thyroiditis10.6
29intestinal disease10.6SST
30prostatitis10.5
31duodenitis10.5
32hyperinsulinemic hypoglycemia, familial, 210.4CHGA, SST
33endocrine gland cancer10.4SST, CHGA
34zollinger-ellison syndrome10.4CHGA, SST
35multiple endocrine neoplasia 110.4CHGA, SST
36serotonin syndrome10.4SST, CHGA
37bladder adenocarcinoma10.4CDX2
38hypercalcemia10.4
39esophageal neuroendocrine tumor10.4
40gastro-enteropancreatic neuroendocrine tumor10.4
41apudoma10.3SST, CALCA
42neuroendocrine carcinoma10.3
43neuronitis10.3
44anal neuroendocrine tumor10.3
45parathyroid adenoma10.3CHGA, CALCA
46factor vii deficiency10.3SST, CHGA
47primary hyperparathyroidism10.3CHGA, CALCA
48prostate cancer10.3
49acute pancreatitis10.3
50laryngeal neuroendocrine tumor10.3

Graphical network of the top 20 diseases related to Neuroendocrine Tumor:



Diseases related to neuroendocrine tumor

Symptoms for Neuroendocrine Tumor

About this section

Drugs & Therapeutics for Neuroendocrine Tumor

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
1
Sutent13 38 SUNITINIB MALATE Pfizer Approved May 2011/ Approved January 2006
FDA Label: Sutent
Malady that Drug Treats: pancreatic neuroendocrine tumors/ Kidney Cancer/Gastrointestinal Stromal Tumors
Indications and Usage:13 SUTENT is a kinase inhibitor indicated for the treatment of:; Gastrointestinal stromal tumor (GIST) after disease progression on or; intolerance to imatinib mesylate. (1.1); Advanced renal cell carcinoma (RCC). (1.2); Progressive, well-differentiated pancreatic neuroendocrine tumors; (pNET) in patients with unresectable locally advanced or metastatic; disease. (1.3)
DrugBank Targets:11 1. Platelet-derived growth factor receptor beta; 2. Vascular endothelial growth factor receptor 1; 3. Mast/stem cell growth factor receptor Kit; 4. Vascular endothelial growth factor receptor 2; 5. Vascular endothelial growth factor receptor 3; 6. Receptor-type tyrosine-protein kinase FLT3; 7. Macrophage colony-stimulating factor 1 receptor; 8. Platelet-derived growth factor receptor alpha
Mechanism of Action:13 
Target: variety of kinases, platelet-derived growth factor receptors (PDGFR± and PDGFR²), vascular endothelial growth factor; receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3; (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor; receptor (RET)
Action: inhibitor
FDA: Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are; implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was; evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor; of platelet-derived growth factor receptors (PDGFR± and PDGFR²), vascular endothelial growth factor; receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3; (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor; receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and; cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary; metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays.; Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFRbð, VEGFR2, KIT) in tumor xenografts; expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or; inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit; growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit; PDGFRbð- and VEGFR2-dependent tumor angiogenesis in vivo.

Drug clinical trials:

Search ClinicalTrials for Neuroendocrine Tumor

Search NIH Clinical Center for Neuroendocrine Tumor

Genetic Tests for Neuroendocrine Tumor

About this section

Anatomical Context for Neuroendocrine Tumor

About this section

MalaCards organs/tissues related to Neuroendocrine Tumor:

31
Pancreas, Lung, Liver, Thyroid, Prostate, Breast, Bone, Pituitary, Small intestine, Kidney, Lymph node, Spleen, Thymus, Colon, Testes, Endothelial, Spinal cord, Cervix, Appendix, Pancreatic islet, Bone marrow, Brain, Heart, Adrenal gland, Pineal, Smooth muscle, Ovary

Animal Models for Neuroendocrine Tumor or affiliated genes

About this section

MGI Mouse Phenotypes related to Neuroendocrine Tumor:

35
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053818.5CDX2, NKX2-1, GHRL, SST, CPE
2MP:00028738.3ASCL1, SST, GHRL, CALCA, NKX2-2, CDX2
3MP:00053798.1CDX2, CPE, CHGA, ASCL1, GHRL, NKX2-2
4MP:00053787.9TPH1, CPE, CHGA, ASCL1, SST, NKX2-2
5MP:00053867.9TPH1, CPE, ASCL1, SST, GHRL, CALCA
6MP:00053767.5TPH1, CPE, CHGA, SST, GHRL, CALCA

Publications for Neuroendocrine Tumor

About this section

Articles related to Neuroendocrine Tumor:

(show top 50)    (show all 896)
idTitleAuthorsYear
1
The potential of neurotensin secreted from neuroendocrine tumor cells to promote gelsolin-mediated invasiveness of prostate adenocarcinoma cells. (25581609)
2015
2
Mid-gut ACTH-secreting neuroendocrine tumor unmasked with (18)F-dihydroxyphenylalanine-positron emission tomography. (25861450)
2015
3
Ectopic ACTH syndrome caused by desmopressin-responsive thymic neuroendocrine tumor. (25819222)
2015
4
Primary large-cell neuroendocrine tumor of the breast. (23458218)
2013
5
Inhibin-expressing clear cell neuroendocrine tumor of the ampulla: an unusual presentation of von Hippel-Lindau disease. (23913169)
2013
6
Tenascin-C downregulates wnt inhibitor dickkopf-1, promoting tumorigenesis in a neuroendocrine tumor model. (24139798)
2013
7
The dedifferentiation of neuroendocrine tumor metastases: myth or reality? (23529331)
2013
8
Endoscopic submucosal dissection of a duodenal neuroendocrine tumor. (24368076)
2013
9
MK-2206 causes growth suppression and reduces neuroendocrine tumor marker production in medullary thyroid cancer through Akt inhibition. (23900743)
2013
10
INSL5 may be a unique marker of colorectal endocrine cells and neuroendocrine tumors. (23438439)
2013
11
99mTc-tektrotyd SPECT/MRI in the diagnosis of a gastroenteropancreatic neuroendocrine tumor. (22391730)
2012
12
Retrospective analysis of seventy-one patients with neuroendocrine tumor and review of the literature. (21618056)
2012
13
Duodenal gastrinoma with multiple gastric neuroendocrine tumors secondary to chronic Helicobacter pylori gastritis. (22588069)
2012
14
Neuroendocrine tumor of the uterine cervix: a clinicopathologic study of 14 cases. (22695823)
2012
15
Neuroendocrine tumor of the cystic duct. (23082709)
2012
16
Somatostatin and dopamine receptor profile of gastroenteropancreatic neuroendocrine tumors: an immunohistochemical study. (21287294)
2011
17
Cushing's syndrome due to a pancreatic neuroendocrine tumor metastatic to the ovaries: a clinicopathological description of a case. (21390554)
2011
18
Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. (20168288)
2010
19
Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. (20817788)
2010
20
ZM447439, a novel promising aurora kinase inhibitor, provokes antiproliferative and proapoptotic effects alone and in combination with bio- and chemotherapeutic agents in gastroenteropancreatic neuroendocrine tumor cell lines. (19923785)
2010
21
Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina. (19845257)
2009
22
Hepatic ablation for neuroendocrine tumor metastases. (20017158)
2009
23
Thyroid metastases from typical carcinoid of the lung differentiating between medullary thyroid carcinoma and neuroendocrine tumor metastasis to the thyroid. (19415998)
2009
24
LKB1 protein expression in neuroendocrine tumors of the lung. (18199157)
2008
25
The effect of transforming growth factor beta on human neuroendocrine tumor BON cell proliferation and differentiation is mediated through somatostatin signaling. (18567806)
2008
26
Gastrointestinal neuroendocrine tumors: a role for targeted therapies? (17639038)
2007
27
Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. (17382271)
2007
28
Non-functioning well-differentiated neuroendocrine tumor of the extrahepatic bile duct: an unusual suspect? (17897922)
2007
29
Familial neuroendocrine tumor syndromes: from genetics to clinical practice. (17001463)
2006
30
RET and neuroendocrine tumors. (17036197)
2006
31
TNF-alpha promoter single nucleotide polymorphisms in gastroenteropancreatic neuroendocrine tumors. (17164537)
2006
32
Peptide receptors in neuroendocrine tumors of the lung as potential tools for radionuclide diagnosis and therapy. (17043625)
2006
33
Identification of DLK1 variants in pituitary- and neuroendocrine tumors. (16403460)
2006
34
The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors? (16428931)
2006
35
Neuroendocrine tumor of small bowel. (15332039)
2004
36
Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors. (15646836)
2004
37
RET and neuroendocrine tumors. (15013219)
2004
38
Circulating ghrelin levels in patients with pancreatic and gastrointestinal neuroendocrine tumors: identification of one pancreatic ghrelinoma. (12843152)
2003
39
Nonsteroidal anti-inflammatory drugs inhibit growth of human neuroendocrine tumor cells via G1 cell-cycle arrest. (14566837)
2003
40
Liver transplantation for metastatic neuroendocrine tumor disease. (12644147)
2003
41
Preoperative localization of a neuroendocrine tumor of the pancreas with EUS-guided fine needle tattooing. (11923783)
2002
42
Tumor markers in neuroendocrine tumors. (10940685)
2000
43
Correlative immunohistochemical and reverse transcriptase polymerase chain reaction analysis of somatostatin receptor type 2 in neuroendocrine tumors of the lung. (10718213)
2000
44
Molecular genetics of neuroendocrine tumors. (10940682)
2000
45
Somatostatin receptor scintigraphy in neuroendocrine tumors exemplified by a patient with hepatic metastases of gastrinoma]. (7513113)
1994
46
A benign neuroendocrine tumor of the lung: study on the origin of the so-called sclerosing hemangioma of the lung]. (8082241)
1994
47
A calcitonin-producing neuroendocrine tumor of the larynx: a case report. (8236510)
1993
48
Immunogold detection of chromogranin A in the neuroendocrine tumor. (8427030)
1993
49
Somatostatin receptor imaging in the diagnosis and treatment of neuroendocrine tumors. (1356013)
1992
50
Detection of functional interferon alpha receptors in human neuroendocrine tumor cell lines using a new monoclonal antibody. (1316782)
1992

Variations for Neuroendocrine Tumor

About this section

Expression for genes affiliated with Neuroendocrine Tumor

About this section
Search GEO for disease gene expression data for Neuroendocrine Tumor.

Pathways for genes affiliated with Neuroendocrine Tumor

About this section

Pathways related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

idSuper pathways (with members indented)ScoreTop Affiliating Genes
19.4NKX2-2, SST, ASCL1, TPH1
29.3MKI67, TPH1, NKX2-2, NKX2-1
3
Show member pathways
9.2CDX2, GHRL, CPE

Compounds for genes affiliated with Neuroendocrine Tumor

About this section

Compounds related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

(show top 50)    (show all 82)
idCompoundScoreTop Affiliating Genes
1lithium chloride4410.3ASCL1, CHGA
2ghrp-628 4411.2SST, GHRL
3lafutidine4410.2SST, CALCA
45-hydroxytryptophan4410.2CHGA, TPH1, SST
55-hydroxyindoleacetic acid44 2411.2TPH1, CHGA, SST
6111in-pentetreotide4410.1CALCA, SST, CHGA
7mibg4410.1CHGA, SST, CALCA
8clonidine44 50 28 1113.0CALCA, SST, CHGA
9oxyntomodulin44 6011.0SST, GHRL, CHGA
10levodopa44 1111.0SST, TPH1, CHGA
11propranolol44 28 50 24 1114.0SST, CHGA, CALCA
12ghrp4410.0GHRL, SST
13cinacalcet44 28 1111.9CALCA, GHRL
14amphetamine44 50 1111.9TPH1, GHRL, SST
15naloxone44 28 50 1112.9SST, GHRL, GGH
16hematoxylin449.9MKI67, CHGA, NKX2-1
17p002449.9CHGA, TPH1, MKI67
18atropine44 28 1111.8SST, CALCA, GHRL
19pramlintide44 1110.8GHRL, CALCA
20gaba449.7CHGA, SST, GHRL, TPH1
21acth449.7GHRL, CHGA, SST, CALCA
22peptidylglycine449.6CPE, CHGA
23amide449.6CHGA, CPE, GHRL
24histamine44 28 2411.5CHGA, SST, GHRL, CALCA
25c-peptide449.5CPE, SST, GHRL, CHGA
26hydrocortisone44 1 60 1112.5GHRL, CALCA, SST
27epinephrine44 24 1111.5MKI67, SST, CHGA, CALCA, GHRL
285-hydroxytryptamine449.5TPH1, CALCA, GHRL, SST, CHGA
29vitamin d449.4CHGA, CDX2, CALCA, GHRL
30norepinephrine44 24 1111.4SST, TPH1, CALCA, GHRL, CHGA
31acetylcholine44 50 28 24 1113.4CHGA, TPH1, SST, CALCA, GHRL
32testosterone44 60 24 1112.4CHGA, CALCA, MKI67, GHRL, SST
33gnrh449.4NKX2-1, GHRL, SST, CHGA, MKI67
34vegf449.3CALCA, MKI67, CHGA, SST, GHRL
35progesterone44 28 60 24 1113.3CHGA, MKI67, NKX2-1, CDX2, TPH1
36octreotide44 60 28 1112.2CHGA, GHRL, CALCA, SST, MKI67, GGH
37paraffin449.2CHGA, MKI67, CDX2, NKX2-1, GHRL
38nitric oxide44 24 1111.2CHGA, MKI67, CALCA, GHRL, TPH1
39lactate449.2GHRL, GGH, MKI67, SST, CHGA, CALCA
40cyclic amp44 2410.2CALCA, GHRL, TPH1, NKX2-1, CHGA
41arginine449.0GHRL, SST, CHGA, TPH1, CPE, MKI67
42fatty acid448.9CDX2, CHGA, GHRL, MKI67
43glucose448.9GHRL, GGH, CPE, SST, MKI67, CHGA
44zinc44 249.8CHGA, CPE, NKX2-1, GHRL, MKI67
45forskolin44 50 1110.7CALCA, GHRL, CHGA, TPH1, CPE, NKX2-1
46dopamine44 28 24 1111.6CALCA, GHRL, ASCL1, SST, CHGA, CPE
47glutamate448.6TPH1, CPE, CHGA, SST, CALCA, GGH
48lysine448.6ASCL1, CPE, HIST1H1B, MKI67
49estrogen448.6CALCA, TPH1, MKI67, CHGA, NKX2-1, GHRL
50tyrosine448.6GHRL, NKX2-1, ASCL1, CHGA, TPH1, MKI67

GO Terms for genes affiliated with Neuroendocrine Tumor

About this section

Cellular components related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1neuronal cell bodyGO:00430259.6CALCA, SST, ASCL1
2transport vesicle membraneGO:00306589.4CHGA, CPE

Biological processes related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1spinal cord oligodendrocyte cell fate specificationGO:002153010.1NKX2-2, ASCL1
2neuron fate specificationGO:004866510.0NKX2-2, ASCL1
3response to heatGO:00094089.9CALCA, SST
4cerebral cortex GABAergic interneuron differentiationGO:00218929.9NKX2-1, ASCL1
5negative regulation of ossificationGO:00302799.9TPH1, CALCA
6oligodendrocyte developmentGO:00140039.8NKX2-2, ASCL1
7response to hormoneGO:00097259.3NKX2-1, GHRL

Sources for Neuroendocrine Tumor

About this section
2CDC
12ExPASy
13FDA
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet